Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing therapies for the localized treatment of diseases affecting the skin and connective tissue. The company not have any approved product in its portfolio at the moment. As a result, the company is yet to generate any revenues.
Fibrocell’s performance over the last four quarters has been encouraging so far with its earnings having surpassed expectations twice while missing the same once. The average trailing four-quarter positive surprise over the last four quarters is 28.30%.
Currently, Fibrocell has a Zacks Rank #1 (Strong Buy) but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Fibrocell reported a loss of 40 cents per share which was wider than the Zacks Consensus Estimate of loss of 33 cents.
Revenues Beat: Fibrocell did generate any revenues in the reported quarter due to lack of any approved product. However, the Zacks consensus estimate was $0.24 million.
Key Stats: Selling, general and administrative expenses were up 14.7% at $1.8 million while research & development expenses increased 18.3% to $1.9 million. Fibrocell is developing its gene therapy candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare, genetic skin disorder. The company’s another clinical candidate, FCX-013, is being developed for the treatment of moderate to severe localized scleroderma.
Share Price Impact: Shares were up almost 1% in pre-market trading.
Fibrocell Science Inc Price and EPS Surprise
Will you retire a millionaire?
One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, “7 Things You Can Do Now to Retire a Multimillionaire.”
Click to get it free >>
Image: Bigstock
Fibrocell (FCSC) Miss Estimates for Earnings & Revenues in Q1
Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing therapies for the localized treatment of diseases affecting the skin and connective tissue. The company not have any approved product in its portfolio at the moment. As a result, the company is yet to generate any revenues.
Fibrocell’s performance over the last four quarters has been encouraging so far with its earnings having surpassed expectations twice while missing the same once. The average trailing four-quarter positive surprise over the last four quarters is 28.30%.
Currently, Fibrocell has a Zacks Rank #1 (Strong Buy) but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Fibrocell reported a loss of 40 cents per share which was wider than the Zacks Consensus Estimate of loss of 33 cents.
Revenues Beat: Fibrocell did generate any revenues in the reported quarter due to lack of any approved product. However, the Zacks consensus estimate was $0.24 million.
Key Stats: Selling, general and administrative expenses were up 14.7% at $1.8 million while research & development expenses increased 18.3% to $1.9 million. Fibrocell is developing its gene therapy candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare, genetic skin disorder. The company’s another clinical candidate, FCX-013, is being developed for the treatment of moderate to severe localized scleroderma.
Share Price Impact: Shares were up almost 1% in pre-market trading.
Fibrocell Science Inc Price and EPS Surprise
Fibrocell Science Inc price-eps-surprise | Fibrocell Science Inc Quote
Will you retire a millionaire?
One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, “7 Things You Can Do Now to Retire a Multimillionaire.”
Click to get it free >>